Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review

The treatment landscape in oncology has witnessed a major revolution with the introduction of checkpoint inhibitors: anti-PD1, anti-PDL1 and anti-CTLA-4. These agents enhance the immune response towards cancer cells instead of targeting the tumor itself, contrary to standard chemotherapy. Although l...

Descripción completa

Detalles Bibliográficos
Autores principales: Haibe, Yolla, El Husseini, Ziad, El Sayed, Rola, Shamseddine, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504220/
https://www.ncbi.nlm.nih.gov/pubmed/32867025
http://dx.doi.org/10.3390/ijms21176176

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7504220/
https://www.ncbi.nlm.nih.gov/pubmed/32867025
http://dx.doi.org/10.3390/ijms21176176

Ejemplares similares